Evidence map›Paper›PMID 38995613›Full record

ArticleJournal of nephrology2024

Impact of COVID-19 vaccines in patients on hemodialysis: an Italian multicentre cohort study.

Salvatore De Masi, Roberto Da Cas, Francesca Menniti Ippolito, Giovanni Baglio, Carmine Zoccali, Flavia Chiarotti, Massimo Fabiani, Francesca Colavita, Concetta Castilletti, Mario Salomone and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Kidney involvement and anemia in COVID-19 infection.World journal of nephrology · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Salvatore De MasiClinical Trial Centre, Careggi Hospital, Florence, Italy.
Roberto Da CasItalian National Institute of Health, Rome, Italy. roberto.dacas@iss.it.
Francesca Menniti IppolitoItalian National Institute of Health, Rome, Italy.
Giovanni BaglioItalian National Agency for Regional Healthcare Services, Rome, Italy.
Carmine ZoccaliRenal Research Institute, New York, USA.
Flavia ChiarottiItalian National Institute of Health, Rome, Italy.
Massimo FabianiItalian National Institute of Health, Rome, Italy.
Francesca ColavitaLaboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Concetta CastillettiDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Mario SalomoneUnit of Nephrology and Dialysis, Chieri and Moncalieri Hospitals, Turin, Italy.
Alfonso MeleItalian National Institute of Health, Rome, Italy.
Piergiorgio MessaUnit of Nephrology, Dialysis, and Renal Transplant, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
COVIDVaxDia Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to evaluate the impact on the national health system of COVID-19 infection in vaccinated patients undergoing haemodialysis.

methodsFrom the cohort of vaccinated dialysis patients enrolled in 118 dialysis centres, we calculated hospitalisation incidence in COVID-19-infected subjects. COVID-19-related hospitalisations and ICU admissions were analysed over two time periods (prior to administration of the third dose and following administration of the third dose of vaccine) and adjusted for several co-variates. Using the general population as the reference, we then calculated the Standardized Incidence Ratio (SIR) of hospitalisation.

resultsEighty-two subjects out of 1096 infected patients were hospitalised (7.5%) and sixty-four hospitalisations occurred among the 824 infected persons after the third dose. Age ≥ 60 years (Adj RR 2.91; 95% CI 1.34-6.30) and lung disease (Adj RR = 2.45; 95% CI 1.32-4.54) were the only risk factors associated with hospitalisation. The risk of ICU admission in the second time period (Time 2) was reduced by 86% (RR = 0.14; 95% CI 0.03-0.71) compared to the first time period (Time 1). The SIR of hospitalisation (SIR 14.51; 95% CI 11.37-17.65) and ICU admission (SIR 14.58; 95% CI 2.91-26.24) showed an increase in the number of events in dialysis patients compared to the general population.

conclusionsOur analysis revealed that while the second variant of the virus increased infection rates, it was concurrently associated with mitigated severity of infections. Dialysis patients exhibited a higher susceptibility to both COVID-19 hospitalisation and ICU admission than the general population throughout the pandemic.

Indexed as

COVID-19COVID-19 VaccinesHospitalizationRenal DialysisAgedCohort StudiesFemaleHumansIncidenceIntensive Care UnitsItalyMaleMiddle AgedRisk FactorsSARS-CoV-2COVID-19 VaccinesCOVID-19 vaccineHemodialysisHospitalisationICU

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.